Militia Capital Management LLC Buys Shares of 94,200 uniQure N.V. $QURE

Militia Capital Management LLC purchased a new stake in shares of uniQure N.V. (NASDAQ:QURE) in the first quarter, according to its most recent filing with the SEC. The firm purchased 94,200 shares of the biotechnology company’s stock, valued at approximately $1,540,000.

Other institutional investors have also modified their holdings of the company. Torren Management LLC acquired a new stake in shares of uniQure in the 4th quarter worth approximately $28,000. IFP Advisors Inc acquired a new position in uniQure during the fourth quarter worth $48,000. Smartleaf Asset Management LLC acquired a new position in uniQure during the fourth quarter worth $48,000. CIBC Private Wealth Group LLC purchased a new stake in uniQure during the third quarter worth $50,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in uniQure by 42.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 906 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Insider Buying and Selling

In other news, insider Walid Abi-Saab sold 30,000 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $46.42, for a total value of $1,392,600.00. Following the sale, the insider directly owned 148,235 shares in the company, valued at $6,881,068.70. This represents a 16.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Matthew C. Kapusta sold 21,082 shares of the stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $45.16, for a total value of $952,063.12. Following the sale, the chief executive officer directly owned 519,227 shares in the company, valued at approximately $23,448,291.32. The trade was a 3.90% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 433,229 shares of company stock valued at $17,944,799 over the last three months. Insiders own 4.65% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on QURE. HC Wainwright upped their target price on uniQure from $50.00 to $80.00 and gave the company a “buy” rating in a report on Monday, June 29th. Wall Street Zen raised uniQure from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Leerink Partners boosted their price objective on shares of uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Cantor Fitzgerald raised shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price objective on the stock in a research note on Wednesday, June 17th. Finally, The Goldman Sachs Group raised their target price on shares of uniQure from $14.00 to $46.00 and gave the company a “neutral” rating in a report on Thursday, June 18th. Twelve investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $64.17.

uniQure Price Performance

QURE stock opened at $40.38 on Thursday. uniQure N.V. has a 1 year low of $8.73 and a 1 year high of $71.50. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40. The stock’s 50 day moving average price is $35.47 and its 200 day moving average price is $25.46. The firm has a market cap of $2.55 billion, a P/E ratio of -11.60 and a beta of 0.90.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. The firm had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. On average, sell-side analysts expect that uniQure N.V. will post -3.56 earnings per share for the current fiscal year.

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.